BACKGROUND: Griffithsin, a 121-residue protein isolated from a red algal Griffithsia sp., binds high mannose N-linked glycans of virus surface glycoproteins with extremely high affinity, a property that allows it to prevent the entry of primary isolates and laboratory strains of T- and M-tropic HIV-1. We used the sequence of a portion of griffithsin's sequence as a design template to create smaller peptides with antiviral and carbohydrate-binding properties. METHODOLOGY/ RESULTS: The new peptides derived from a trio of homologous β-sheet repeats that comprise the motifs responsible for its biological activity. Our most active antiviral peptide, grifonin-1 (GRFN-1), had an EC50 of 190.8±11.0 nM in in vitro TZM-bl assays and an EC(50) of 546.6±66.1 nM in p24gag antigen release assays. GRFN-1 showed considerable structural plasticity, assuming different conformations in solvents that differed in polarity and hydrophobicity. Higher concentrations of GRFN-1 formed oligomers, based on intermolecular β-sheet interactions. Like its parent protein, GRFN-1 bound viral glycoproteins gp41 and gp120 via the N-linked glycans on their surface. CONCLUSION: Its substantial antiviral activity and low toxicity in vitro suggest that GRFN-1 and/or its derivatives may have therapeutic potential as topical and/or systemic agents directed against HIV-1.
BACKGROUND: Griffithsin, a 121-residue protein isolated from a red algal Griffithsia sp., binds high mannose N-linked glycans of virus surface glycoproteins with extremely high affinity, a property that allows it to prevent the entry of primary isolates and laboratory strains of T- and M-tropic HIV-1. We used the sequence of a portion of griffithsin's sequence as a design template to create smaller peptides with antiviral and carbohydrate-binding properties. METHODOLOGY/ RESULTS: The new peptides derived from a trio of homologous β-sheet repeats that comprise the motifs responsible for its biological activity. Our most active antiviral peptide, grifonin-1 (GRFN-1), had an EC50 of 190.8±11.0 nM in in vitro TZM-bl assays and an EC(50) of 546.6±66.1 nM in p24gag antigen release assays. GRFN-1 showed considerable structural plasticity, assuming different conformations in solvents that differed in polarity and hydrophobicity. Higher concentrations of GRFN-1 formed oligomers, based on intermolecular β-sheet interactions. Like its parent protein, GRFN-1 bound viral glycoproteins gp41 and gp120 via the N-linked glycans on their surface. CONCLUSION: Its substantial antiviral activity and low toxicity in vitro suggest that GRFN-1 and/or its derivatives may have therapeutic potential as topical and/or systemic agents directed against HIV-1.
Authors: Heidi R Bokesch; Romila D Charan; Karina M Meragelman; John A Beutler; Roberta Gardella; Barry R O'Keefe; Tawnya C McKee; James B McMahon Journal: FEBS Lett Date: 2004-06-04 Impact factor: 4.124
Authors: Barbara Giomarelli; Kathryn M Schumacher; Troy E Taylor; Raymond C Sowder; James L Hartley; James B McMahon; Toshiyuki Mori Journal: Protein Expr Purif Date: 2005-11-07 Impact factor: 1.650
Authors: Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw Journal: Nature Date: 2003-03-20 Impact factor: 49.962
Authors: Natasza E Ziółkowska; Shilpa R Shenoy; Barry R O'Keefe; James B McMahon; Kenneth E Palmer; Raymond A Dwek; Mark R Wormald; Alexander Wlodawer Journal: Proteins Date: 2007-05-15
Authors: Matthew P Wood; Amy L Cole; Piotr Ruchala; Alan J Waring; Lisa C Rohan; Preston Marx; Patrick M Tarwater; Phalguni Gupta; Alexander M Cole Journal: PLoS One Date: 2013-02-05 Impact factor: 3.240
Authors: Javier Echave; Paz Otero; Paula Garcia-Oliveira; Paulo E S Munekata; Mirian Pateiro; Jose M Lorenzo; Jesus Simal-Gandara; Miguel A Prieto Journal: Antioxidants (Basel) Date: 2022-01-17